PCM
SRPT icon

Pinz Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Pinz Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,216
Closed -$157K – 310
2019
Q4 		$157K Buy
+1,216
New +$123K 0.06% 110

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Pinz Capital Management's SRPT Position: Q1 2020 in Review

Pinz Capital Management sold out of Sarepta Therapeutics (SRPT) in Q1 2020, closing a stake of 1,216 shares — an estimated $157K sold.

Pinz Capital Management first reported a position in SRPT in Q4 2019 and held it in 1 quarter. The position peaked at $157K in Q4 2019. 365 funds tracked by Wall St. Rank hold SRPT as of Q1 2020.

  • Pinz Capital Management reported no remaining Sarepta Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Pinz Capital Management sold 1,216 Sarepta Therapeutics shares in Q1 2020, an estimated $157K.
  • Pinz Capital Management first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 1 quarter.
  • Pinz Capital Management's Sarepta Therapeutics position peaked at $157K in Q4 2019.
  • 365 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2020.

Based on Pinz Capital Management's 13F filing for Q1 2020, filed 12 May 2020.